NADAC acquisition cost data for RECTIV 0.4% OINTMENT. This is a brand-name medication — generic alternatives may be available at lower prices.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 58914030180 | $20.44 | 2022-02-23 | Rx |
| 58914030180 | $20.44 | 2022-02-23 | Rx |
| 58914030180 | $20.44 | 2022-02-23 | Rx |
| 58914030180 | $20.44 | 2022-02-23 | Rx |
| 58914030180 | $20.44 | 2022-02-23 | Rx |
| 58914030180 | $20.44 | 2022-02-23 | Rx |
| 58914030180 | $20.44 | 2022-02-23 | Rx |
| 58914030180 | $20.44 | 2022-02-23 | Rx |
| 58914030180 | $20.44 | 2022-02-23 | Rx |
| 58914030180 | $20.44 | 2022-02-23 | Rx |
Generic: Nitroglycerin | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | $2.0M | 2,946 | 1,980 | $21.75 |
| 2020 | $4.0M | 5,772 | 3,747 | $21.81 |
| 2021 | $4.7M | 6,525 | 4,009 | $22.13 |
| 2022 | $5.2M | 7,158 | 4,409 | $22.40 |
| 2023 | $5.8M | 8,160 | 5,041 | $22.61 |
These generic drugs may be equivalent alternatives at lower prices.
| State | Total Cost | Claims | Beneficiaries |
|---|---|---|---|
| New York | $941.3K | 1,319 | 564 |
| California | $740.8K | 1,069 | 633 |
| New Jersey | $504.3K | 558 | 214 |
| Florida | $322.2K | 464 | 327 |
| Connecticut | $268.9K | 381 | 245 |
| Texas | $253.9K | 356 | 257 |
| Pennsylvania | $216.1K | 320 | 214 |
| Massachusetts | $207.9K | 299 | 191 |
| Illinois | $197.1K | 278 | 186 |
| North Carolina | $173.6K | 245 | 177 |
| Ohio | $156.1K | 225 | 161 |
| Washington | $130.9K | 193 | 138 |
| Virginia | $128.5K | 183 | 110 |
| Minnesota | $127.6K | 188 | 106 |
| Michigan | $124.8K | 187 | 136 |
| Wisconsin | $86.8K | 121 | 92 |
| Oregon | $77.0K | 111 | 75 |
| Arizona | $74.6K | 102 | 84 |
| Missouri | $71.7K | 103 | 72 |
| Georgia | $69.2K | 98 | 79 |
| Tennessee | $66.7K | 97 | 66 |
| Colorado | $64.0K | 90 | 64 |
| Maryland | $63.8K | 89 | 57 |
| South Carolina | $60.5K | 89 | 74 |
| Indiana | $59.4K | 84 | 76 |
| Louisiana | $55.7K | 82 | 67 |
| Alabama | $50.6K | 73 | 63 |
| Nevada | $47.8K | 68 | 46 |
| Kentucky | $41.9K | 61 | 46 |
| Maine | $41.3K | 60 | 42 |
| Arkansas | $38.4K | 56 | 32 |
| New Mexico | $35.1K | 53 | 44 |
| Rhode Island | $33.8K | 48 | 30 |
| Oklahoma | $32.0K | 45 | 28 |
| Iowa | $29.3K | 43 | 33 |
| Mississippi | $25.8K | 38 | 22 |
| Hawaii | $24.6K | 36 | 27 |
| Kansas | $19.4K | 29 | 26 |
| Vermont | $17.6K | 26 | 19 |
| Idaho | $17.1K | 26 | 20 |
| Delaware | $14.4K | 21 | 18 |
| West Virginia | $14.3K | 22 | 13 |
| New Hampshire | $13.9K | 20 | 15 |
| Nebraska | $13.8K | 19 | 17 |
| Puerto Rico | $13.0K | 20 | 16 |
| Montana | $10.8K | 16 | 15 |
| Utah | $9.4K | 14 | 12 |
| Alaska | $8.0K | 12 | N/A |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.